For decades, the medical community has approached the treatment of obesity in older adults with extreme caution. Concerns regarding frailty, the physiological burden of comorbidities, and the risk of adverse drug reactions have often relegated weight management to lifestyle counseling alone. However, a groundbreaking new analysis of the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial program suggests that this paradigm may be shifting.
New research, led by Professor Luca Busetto of the University of Padova in Italy, indicates that semaglutide—the active pharmacological agent in the blockbuster medications Wegovy and Ozempic—is both effective and manageable for patients aged 65 and older. The findings, which demonstrate significant weight loss and cardiometabolic improvements, offer a potential new tool for clinicians tasked with treating an aging population struggling with obesity.
Main Facts: A Landmark Analysis of Weight Loss Efficacy
The study, which pooled data from six distinct STEP clinical trials (STEP 1, 3, 4, 5, 8, and 9), sought to isolate the experiences of older adults from the broader datasets. By focusing on 358 participants aged 65 and older—all of whom struggled with obesity but did not have diabetes—researchers were able to provide a high-resolution look at how GLP-1 receptor agonists function in a demographic often excluded from or underrepresented in initial drug trials.
The headline finding is clear: older adults who received a weekly 2.4 mg dose of semaglutide achieved weight loss results comparable to their younger counterparts in previous studies. By the 68-week mark, participants on semaglutide had shed an average of 15.4% of their body weight, a stark contrast to the 5.1% reduction seen in the placebo group. Beyond the scale, the medication demonstrated clear benefits in reducing waist circumference, improving BMI categories, and stabilizing key cardiometabolic markers, including blood pressure and cholesterol levels.
The Chronology of the Research
The path to these findings involved a rigorous aggregation of data across several years of clinical development.
- Trial Selection: The research team selected trials specifically focused on individuals with obesity or overweight, excluding those with diabetes to ensure that the weight loss metrics were not skewed by the drug’s glycemic-control effects.
- The Enrollment Phase: Participants were selected based on a body mass index (BMI) of at least 30 kg/m², or 27 kg/m² with at least one weight-related complication. The cohort included 248 individuals receiving the active 2.4 mg dose and 110 receiving a placebo.
- The 68-Week Intervention: Throughout the 68-week duration of the trials, participants underwent regular monitoring. All groups were subject to lifestyle interventions, with the STEP 3 subgroup receiving additional intensive behavioral therapy.
- Evaluation and Data Synthesis: Researchers measured body composition changes (waist-to-height ratio, waist circumference), cardiometabolic risk factors (hs-CRP, blood lipids, glucose measures), and tracked the incidence of adverse events (AEs).
- Final Synthesis: The data was finalized by Prof. Busetto’s team, including collaborators from Novo Nordisk, to determine whether the risk-benefit profile of semaglutide remained favorable in an elderly cohort characterized by greater medical vulnerability.
Supporting Data: Translating Success into Metrics
The strength of the study lies in its granular breakdown of weight-loss success. The data suggests that for the aging population, semaglutide is not merely a weight-loss tool but a mechanism for achieving significant health-span improvements.
Weight Loss Milestones
The clinical significance of the medication is perhaps best illustrated by the percentage of participants reaching specific weight-loss thresholds:
- 10% Weight Loss: 66.5% of the semaglutide group achieved this benchmark, compared to only 15.5% in the placebo group.
- 15% Weight Loss: Nearly half (46.8%) of the treatment group reached this milestone, while only 6.4% of the placebo group did so.
- 20% Weight Loss: A notable 28.6% of those on semaglutide saw a fifth of their body weight evaporate, compared to a negligible 2.7% in the control group.
Cardiometabolic and Anthropometric Gains
Beyond total weight loss, the physiological markers of health showed marked improvement. Waist circumference, a primary predictor of visceral fat and cardiovascular risk, dropped by an average of 14.3 cm in the treatment group, nearly triple the 6.0 cm reduction seen in the placebo arm. Furthermore, 27% of semaglutide users moved into the "healthy" BMI category (less than 27 kg/m²), a shift that could significantly reduce the burden of obesity-related chronic diseases like hypertension and non-alcoholic fatty liver disease.
Official Responses and Safety Considerations
The safety profile of semaglutide remains a primary point of discussion for clinicians working with older patients. Because this demographic is more likely to experience frailty or existing organ impairment, the investigators monitored adverse events with heightened scrutiny.
The Safety Profile
Overall rates of adverse events were relatively similar between the semaglutide group (89.1%) and the placebo group (84.5%). However, the study noted that "serious" adverse events were reported more frequently in the treatment group (19.0%) than in the placebo group (12.7%).
Dr. Busetto and his team were quick to note that common side effects—specifically constipation and dizziness—were more frequent among those receiving the drug. These are well-documented gastrointestinal and vasomotor effects of GLP-1 receptor agonists. Importantly, incidents of hypoglycemia and bone fractures, which are high-priority concerns for geriatric patients, remained low and were statistically similar between both the treatment and control groups.
Perspectives from the Lead Investigators
Professor Busetto emphasized that while the findings are positive, they must be interpreted within the context of the patients’ existing vulnerabilities. "In many high-income countries, the majority of cases of excess weight occur in adults aged 65 and over," he noted. By addressing this, the medical community can potentially mitigate the "major driver for obesity-related complications" that currently limits the quality of life and increases disability rates in the elderly.
The inclusion of Novo Nordisk researchers in the study highlights the manufacturer’s commitment to expanding the label of their weight-loss products to ensure that clinical guidelines reflect the needs of the aging population.
Implications for Future Medical Practice
The results of this analysis carry profound implications for the future of geriatric medicine. For years, the "obesity paradox" in older adults—where excess weight was sometimes erroneously thought to be protective against frailty—led to a "hands-off" approach to weight management. This new evidence suggests that, when carefully administered, pharmacological intervention can reverse the detrimental effects of obesity without the significant risks that were once feared.
Improving Quality of Life
The reduction in waist-to-height ratio (WHtR) is a particularly vital finding. As patients age, the redistribution of fat to the abdominal cavity increases the risk of metabolic syndrome. By successfully lowering this ratio, semaglutide may offer a preventative strategy against the cardiovascular events that are the leading cause of mortality in this age group.
A New Standard of Care?
As clinicians look to the future, these findings likely signal a shift in how obesity is prioritized in senior care. Rather than accepting obesity as an inevitable consequence of aging, physicians may now feel empowered to prescribe GLP-1 agonists to help patients regain mobility, improve glycemic control, and reduce the systemic inflammation marked by hs-CRP levels.
The Need for Continued Monitoring
While the data is robust, researchers advise that the implementation of semaglutide in older populations should be personalized. Because the risk of serious adverse events was slightly elevated, the medical community will need to establish clear protocols for dosing, monitoring for signs of dehydration or excessive muscle mass loss, and ensuring that nutritional intake remains sufficient.
In conclusion, the analysis of the STEP trials provides a compelling argument for the utility of semaglutide in older adults. By bridging the gap between clinical trial data and the realities of geriatric practice, this research marks a significant step forward in the treatment of obesity across the lifespan, suggesting that it is never too late to address the metabolic health of the aging population.
